ZENTIVA S.A. (SCD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ZENTIVA S.A. (SCD) has a cash flow conversion efficiency ratio of 0.012x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (RON18.49 Million ≈ $4.24 Million USD) by net assets (RON1.50 Billion ≈ $343.69 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ZENTIVA S.A. liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
ZENTIVA S.A. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how ZENTIVA S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
ZENTIVA S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ZENTIVA S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
EZTEC Empreendimentos e Participações S.A
SA:EZTC3
|
0.042x |
|
Swissquote Group Holding SA
SW:SQN
|
0.300x |
|
Shandong Keyuan Pharmaceutical Co. Ltd. A
SHE:301281
|
N/A |
|
Patria Investments Ltd
NASDAQ:PAX
|
0.058x |
|
Dodla Dairy Limited
NSE:DODLA
|
0.024x |
|
Shengyuan Environmental Protection
SHE:300867
|
0.021x |
|
Jiangsu Jibeier Pharmaceutical Co Ltd
SHG:688566
|
0.004x |
|
Plato Income Maximiser Ltd
AU:PL8
|
0.027x |
Annual Cash Flow Conversion Efficiency for ZENTIVA S.A. (2019–2024)
The table below shows the annual cash flow conversion efficiency of ZENTIVA S.A. from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see ZENTIVA S.A. (SCD) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | RON1.44 Billion ≈ $331.01 Million |
RON85.10 Million ≈ $19.54 Million |
0.059x | +395.83% |
| 2023-09-30 | RON1.19 Billion ≈ $273.53 Million |
RON14.18 Million ≈ $3.26 Million |
0.012x | -42.22% |
| 2022-09-30 | RON999.35 Million ≈ $229.47 Million |
RON20.59 Million ≈ $4.73 Million |
0.021x | -90.37% |
| 2021-09-30 | RON890.77 Million ≈ $204.54 Million |
RON190.64 Million ≈ $43.77 Million |
0.214x | +292.19% |
| 2020-09-30 | RON785.36 Million ≈ $180.33 Million |
RON42.86 Million ≈ $9.84 Million |
0.055x | +283.52% |
| 2019-09-30 | RON702.00 Million ≈ $161.19 Million |
RON-20.87 Million ≈ $-4.79 Million |
-0.030x | -- |
About ZENTIVA S.A.
Zentiva S.A. engages in the production and marketing of preparations and medicines for human use in Romania and internationally. The company develops pharmaceutical products in various therapeutic areas, such as cardiovascular diseases, anti-inflammatory and pain-relieving medications, urologists, blood diseases, gastrointestinal and metabolic disorders, central nervous system, infections, respir… Read more